Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier and get trading ideas, historical data, advanced options screeners, more. FREE 30 Day Trial
Stocks | Futures | Watchlist | More
or
Neurocrine Bioscienc (NBIX)
Neurocrine Bioscienc (NBIX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 9,008,123
  • Shares Outstanding, K 97,575
  • Annual Sales, $ 1,489 M
  • Annual Income, $ 154,500 K
  • 60-Month Beta 0.48
  • Price/Sales 5.98
  • Price/Cash Flow 51.18
  • Price/Book 5.28
Trade NBIX with:

Options Overview Details

View History
  • Implied Volatility 32.62% ( -0.24%)
  • Historical Volatility 24.80%
  • IV Percentile 25%
  • IV Rank 30.79%
  • IV High 51.08% on 10/20/22
  • IV Low 24.41% on 03/30/23
  • Put/Call Vol Ratio 7.54
  • Today's Volume 410
  • Volume Avg (30-Day) 467
  • Put/Call OI Ratio 0.92
  • Today's Open Interest 7,782
  • Open Int (30-Day) 8,055

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 23 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/23
See More
  • Average Estimate 0.72
  • Number of Estimates 11
  • High Estimate 0.95
  • Low Estimate 0.44
  • Prior Year -0.18
  • Growth Rate Est. (year over year) +500.00%

Price Performance

See More
Period Period Low Period High Performance
1-Month
89.04 +3.68%
on 05/30/23
107.98 -14.50%
on 05/03/23
-11.13 (-10.76%)
since 05/02/23
3-Month
89.04 +3.68%
on 05/30/23
107.98 -14.50%
on 05/03/23
-7.84 (-7.83%)
since 03/02/23
52-Week
88.38 +4.46%
on 06/16/22
129.29 -28.59%
on 12/01/22
-2.10 (-2.22%)
since 06/02/22

Most Recent Stories

More News
Neurocrine Biosciences Presents INGREZZA® (valbenazine) Capsules Data on Tardive Dyskinesia Improvement Regardless of Baseline Antipsychotic Use at 2023 Psych Congress Elevate

/PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today presented findings from a meta-analysis of three long-term studies evaluating INGREZZA®...

NBIX : 92.32 (+1.24%)
Neurocrine Biosciences Announces Publication of Full KINECT™-HD Phase 3 Study Results of Valbenazine for the Treatment of Chorea Associated with Huntington's Disease in The Lancet Neurology

- Statistically Significant Improvement in Chorea Associated with Huntington's Disease Seen as Early as Week 2 - Chorea Improvement Supported by Statistically...

NBIX : 92.32 (+1.24%)
Neurocrine Biosciences Presents INGREZZA® (valbenazine) Capsules Data on Long-Term Improvements and Psychiatric Stability in Patients With Tardive Dyskinesia and Schizophrenia or Schizoaffective Disorder at the Schizophrenia International Research Society

/PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced findings from a post hoc analysis of two long-term studies (KINECT™ 3 and KINECT™...

NBIX : 92.32 (+1.24%)
Neurocrine Biosciences Presents Data on Treatment of Patients with Congenital Adrenal Hyperplasia at ECE 2023

/PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX), a leading neuroscience-focused biopharmaceutical company, today announced that it will present new...

NBIX : 92.32 (+1.24%)
Neurocrine Biosciences (NBIX) Reports Q1 Loss, Tops Revenue Estimates

Neurocrine (NBIX) delivered earnings and revenue surprises of -403.85% and 1.80%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?

NBIX : 92.32 (+1.24%)
ALPN : 10.53 (+2.83%)
Neurocrine: Q1 Earnings Snapshot

Neurocrine: Q1 Earnings Snapshot

NBIX : 92.32 (+1.24%)
Neurocrine Biosciences Reports First Quarter 2023 Financial Results

/PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced its financial results for the first quarter ended March 31, 2023 and provided an...

NBIX : 92.32 (+1.24%)
Neurocrine Biosciences to Present at the Bank of America Securities 2023 Healthcare Conference

/PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) will present at the Bank of America Securities 2023 Healthcare Conference at 10:00 a.m. Pacific...

NBIX : 92.32 (+1.24%)
Neurocrine Biosciences Supports the Mental Health Community During Tardive Dyskinesia Awareness Week

/PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced its continued support of increasing awareness regarding the prevalence, impact and...

NBIX : 92.32 (+1.24%)
Healthy Returns: This A Rated Healthcare Stock Is a Must-Watch for May

Given the pharmaceutical industry’s robust growth prospects, drug-maker Neurocrine Biosciences’ (NBIX) stock is worth watching ahead of its first-quarter earnings next week. Read on… Investors...

NBIX : 92.32 (+1.24%)
NVO : 157.14 (-0.53%)
NVS : 98.91 (+1.85%)
TAK : 16.12 (+1.45%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 100% Sell with a Average short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

Neurocrine Biosciences is a neuroscience-based company focused on the discovery and development of novel therapeutics for neuropsychiatric, neuroinflammatory and neurodegenerative diseases and disorders. The company's neuroscience, endocrine and immunology disciplines provide a unique biological understanding...

See More

Key Turning Points

3rd Resistance Point 95.04
2nd Resistance Point 93.78
1st Resistance Point 93.05
Last Price 92.32
1st Support Level 91.07
2nd Support Level 89.81
3rd Support Level 89.08

See More

52-Week High 129.29
Fibonacci 61.8% 113.66
Fibonacci 50% 108.83
Fibonacci 38.2% 104.01
Last Price 92.32
52-Week Low 88.38

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar